IKIrina G. Kondzhariya

Irina G. Kondzhariya

*This is an algorithmically generated author record based on publicly available information.

Irina G. Kondzhariya has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cytokine response to bacterial translocation in a model of inflammatory bowel diseases in Macaca Mulatta monkeys

    by S. T. Amaba, I. G. Konjaria, A. Z. Matua, Kh. Z. Trapsh, Z. Ya. Mikvabiya, A. G. Dyachenko, С. Т. Амаба, И. Г. Конджария, А. З. Матуа, Х. З. Трапш, et al.

    Inflammatory bowel diseases (IBD) comprise a heterogeneous group of disorders with various clinical and morphological manifestations representing significant issues in modern medicine. The aim of our study was to reproduce the signs of IBD in Macaca mulatta (Rhesus macaque) by oral administration of sodium dextran sulfate (DSS), and to assess the cytokine response to induced damage of intestinal barrier and translocation of bacterial components to the bloodstream. Mature Macaca mulatta males (n = 5), kept in the monkey breeding facility at the Research Institute of Experimental Pathology and Therapy were selected as the object of this study. Induction of inflammatory bowel disease in Rhesus macaque was carried out by oral administration of 5% sodium salt of sulfated dextran (DSS) (molecular weight of 40 000) at the volumes corresponding to physiological needs of animals. Immunological and molecular biology methods were used to determine cytokines and the microbial translocation markers. The results of the study showed that induction of IBD in Rhesus monkeys leads to a regular increase in the serum marker of 16S rDNA translocation from the 2nd day after DSS treatment, reaching maximum values on the sixth day. In parallel with increased bacterial translocation, we have revealed an increase in the cytokine response, i.e., a significant increase in the IL-6 and IFNγ concentrations. The stimulation of cytokine production in response to IBD induction was observed at the early stages, beginning from the 1st day, and reached its peak values on the 2nd to 6th days of exposure. It should be noted that the levels of inflammation markers remained high after the discontinuation of DSS, although they showed a gradual decrease towards the end of the experiment. Hence, a model of chemically induced inflammatory process in Macaca mulatta has been developed, characterized by a distinct, predominantly Th1cytokine profile, accompanied by pronounced microbial translocation. The duration of acute inflammation induced by DSS is comparable to the time required for transition into a chronic form. This model is a potentially valuable tool for further studying the pathogenesis and developing new treatments for IBD.

  • Open Access

    Safety, immunogenicity, and protective efficacy of the intranasal live pertussis vaccine GamLPV in an infant monkey model (Papio hamadryas)

    by D. T. Kubrava, A. Yu. Medkova, A. Z. Matua, I. G. Kondzariya, A. A. Amichba, Kh. Z. Trapsh, L. V. Gamgiya, S. G. Kulikov, L. N. Sinyashina, Z. Ya. Mikvabiya, et al.

    INTRODUCTION. The current progressive increase in pertussis incidence and infant mortality rates is due to the insufficient effectiveness of existing vaccines, both in Russia and worldwide. Previous clinical trials showed that healthy adult volunteers developed long-term antibacterial immunity after vaccination with GamLPV, an intranasal recombinant live pertussis vaccine developed by the National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya. Further clinical development of GamLPV in paediatric volunteers, including infants, requires preclinical studies in a newborn monkey model.AIM. This study aimed to evaluate the safety, immunogenicity, and protective efficacy of the GamLPV vaccine in infant hamadryas baboons (Papio hamadryas) challenged with pertussis after intranasal vaccination.MATERIALS AND METHODS. The study used 20 hamadryas baboons, including 7 infants aged 1–1.5 months, 7 mothers of these infants, and 6 control animals. The study examined the time course of changes in serum levels of specific IgG antibodies to pertussis toxin (PT) and filamentous haemagglutinin (FHA) by enzyme-linked immunosorbent assay (ELISA), monitored changes in serum levels of Bordetella pertussis antibodies by agglutination immunoassay, and detected B. pertussis DNA in oropharyngeal aspirates by real-time polymerase chain reaction.RESULTS. Intranasal GamLPV administration to infant baboons induced the production of specific IgG antibodies to PT and FHA (ELISA) and an increase in the total pertussis antibody titre (agglutination immunoassay). GamLPV did not cause any injection site or systemic reactions. There were no changes in complete blood counts and serum biochemistry profiles after vaccination. The protective efficacy of GamLPV against B. pertussis was demonstrated in challenge tests, where immunised animals had no clinical signs or laboratory findings indicative of pertussis in contrast to controls.CONCLUSIONS. The study demonstrated the safety and immunogenicity of the intranasal live pertussis vaccine GamLPV in newborn hamadryas baboons. GamLPV shows promise in the primary vaccination of infants, the revaccination of children and adults, and the development of herd immunity against pertussis in families.


  • Open Access

    Safety and immunogenicity of live intranasal pertussis vaccine GamLVP in the experimental infant hamadryas baboon model

    by A. A. Djidaryan, A. Z. Matua, A. Yu. Medkova, E. G. Semin, L. N. Sinyashina, I. N. Dyakov, I. N. Chernyshova, D. T. Kubrava, A. A. Amichba, I. G. Kondzariya, et al.

    Introduction. The Gamaleya National Center of Epidemiology and Microbiology has developed a live intranasal pertussis vaccine, GamLVP, for protection against whooping cough. It is indicated for vaccination of infants and revaccination of adults of all age groups. Preclinical studies on suckling mice or rats and adult monkeys as well as clinical trials involving adult volunteers demonstrated safety and efficacy of the GamLVP vaccine. The expansion of the GamLVP vaccine to be used for vaccination of infants requires additional preclinical studies to assess its safety and immunogenicity in the most suitable experimental model of infant hamadryas baboons (Papio hamadryas).The aim of the study was to assess safety and immunogenicity of the GamLVP vaccine administered intranasally for a single dose, two-dose, and three-dose immunization of P. hamadryas infants.Materials and methods. The study was performed in three 1–2-month-old P. hamadryas infants kept, together with their mothers, in a separate cage. The results of the complete blood count and biochemical profile tests were measured before and after the immunization and experimental infection. The enzyme immunoassay (EIA) was used to detect any changes in the levels of specific IgG antibodies in sera from the mothers and infants; the agglutination test (AT) was used to measure titers of total anti-pertussis antibodies.Results. The intranasal immunization of P. hamadryas infants with the GamLVP vaccine triggered development of a specific humoral immune response mediated by IgG antibodies (pertussis toxin + filamentous hemagglutinin), increased titers of total agglutinating anti-pertussis antibodies, caused no local and systemic reactions, caused no changes in the complete blood count and biochemical profile. The experimental infection of the GamLVPimmunized P. hamadryas infants did not cause any changes in the laboratory blood test values and any clinical manifestations typical of the pertussis infection.


  • Open Access

    Preclinical studies of safety, immunogenicity and protective activity of attenuated Bordetella pertussis bacteria on the Macaca mulatta model

    by Алиса Юрьевна Медкова, Lyudmila N. Sinyashina, Астанда Арнольдовна Амичба, Evgeniy G. Semin, Zinaida V. Shevtsova, Алиса Зауровна Матуа, Anush A. Djidaryan, Дженни Тамазовна Кубрава, Irina G. Kondzhariya, Vladimir S. Barkaya, et al.

    Introduction. An increasing incidence of pertussis among different groups of population and shortcomings of the existing preventive solutions pinpoint urgency of development of new safe vaccines suitable for immunization of infants and for booster immunization of adolescents and adults.The purpose of this study is evaluation of safety, immunogenicity and protective activity of the new constructed attenuated Bordetella pertussis bacteria 4MKS by infecting immunized Macaca mulatta monkeys intranasally with virulent bacteria of the pertussis pathogen.Materials and methods. Five adult, clinically healthy Macaca mulatta monkeys aged 3–4 years were used for immunization and experimental infection. The re-immunization was performed in 6 months. Three non-immunized animals of the same age were used as controls.Results. The intranasal single-dose inoculation and re-inoculation of attenuated B. pertussis bacteria did not cause any nasopharyngeal inflammation in the rhesus monkeys and any changes in the blood lab test values after the nonhuman primates had been infected with virulent bacteria. No elevation of total IgE was detected in blood serum of the Macaca mulatta monkeys after the single-dose and double-dose immunization. When the monkeys were intranasally immunized with attenuated and virulent B. pertussis bacteria, they developed a defensive reaction to re-infection, namely suppression of the bacterial growth, increased rates of elimination of bacteria from the animals’ nasopharynxes and development of a humoral immune response to the infection. The development of immunity against pertussis re-infection is accompanied by a pronounced booster effect.Discussion. The obtained results suggest common mechanisms of development both of post-vaccination immunity after intranasal vaccination of animals and infection-acquired immunity against pertussis. Both of them provide protection against re-infection with B. pertussis bacteria and prevent development of clinical symptoms of pertussis.